Nonrelapse mortality and mycophenolic acid exposure in Nonmyeloablative Hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 8, 2013, Pages 1159-1166

  McDermott, Cara L ^a   Sandmaier, Brenda M ^b,c   Storer, Barry ^c   Li, Hong ^d   Mager, Donald E ^d   Boeckh, Michael J ^b,c   Bemer, Meagan J ^c   Knutson, Jennifer ^a   McCune, Jeannine S ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bayesian; Graft versus host disease; Hematopoietic cell transplant; Mycophenolic acid; Pharmacokinetics

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHIMERA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE CLASSIFICATION; DONOR; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; STEADY STATE; T LYMPHOCYTE; VIRUS REACTIVATION; WHOLE BODY RADIATION;

BAYESIAN; GRAFT VERSUS HOST DISEASE; HEMATOPOIETIC CELL TRANSPLANT; MYCOPHENOLIC ACID; PHARMACOKINETICS;

ADOLESCENT; ADULT; AGED; BAYES THEOREM; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84880433955     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.026     Document Type: Article

References (38)

1. Mineishi S. Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go. JAMA 2011, 306:1918-1920.
2. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011, 306:1874-1883.
3. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003, 102:2021-2030.
4. Nash R.A., Johnston L., Parker P., et al. Aphase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005, 11:495-505.
5. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
6. Maris M.B., Sandmaier B.M., Storer B.E., et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006, 12:454-465.
7. Giaccone L., McCune J.S., Maris M.B., et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005, 106:4381-4388.
8. Royer B., Larosa F., Legrand F., et al. Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. Biol Blood Marrow Transplant 2009, 15:1134-1139.
9. Osunkwo I., Bessmertny O., Harrison L., et al. Apilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004, 10:246-258.
10. Haentzschel I., Freiberg-Richter J., Platzbecker U., et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant 2008, 42:113-120.
11. Saint-Marcoux F., Guigonis V., Decramer S., et al. Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacol Res 2011, 63:423-431.
12. Jenke A., Renner U., Richte M., et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001, 15:176-184.
13. Bhatia M., Militano O., Jin Z., et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010, 16:333-343.
14. Jacobson P., Rogosheske J., Barker J.N., et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005, 78:486-500.
15. Li H., Mager D.E., Bemer M.J., et al. Population pharmacokinetics and dose optimization of mycophenolic acid in hct recipients receiving oral mycophenolate mofetil. JClin Pharmacol 2013, 53:393-402.
16. Tsina I., Chu F., Hama K., et al. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. JChromatogr B Biomed Appl 1996, 675:119-129.
17. Renner U.D., Thiede C., Bornhauser M., et al. Determination of mycophenolic acid and mycophenolate mofetil by high-performance liquid chromatography using postcolumn derivatization. Anal Chem 2001, 73:41-46.
18. Nowak I., Shaw L.M. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995, 41:1011-1017.
19. Bryant E., Martin P.J. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. Hematopoietic cell transplantation 1999, 197-206. Blackwell Science, Inc., Malden, MA. E.D. Thomas, K.G. Blume, S.J. Forman (Eds.).
20. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
21. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991, 28:250-259.
22. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
23. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
24. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
25. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
26. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004, 104:2254-2262.
27. Ram R., Storer B., Mielcarek M., et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:414-422.
28. Baron F., Little M.T., Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev 2005, 19:153-164.
29. Deeg H.J., Maris M.B., Scott B.L., Warren E.H. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 2006, 20:1701-1705.
30. Baron F., Sandmaier B.M., Storer B.E., et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 2007, 13:1041-1048.
31. de Winter B.C., Mathot R.A., Sombogaard F., et al. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. Ther Drug Monit 2010, 32:606-614.
32. Li H., Mager D.E., Bemer M.J., et al. Alimited sampling schedule to estimate mycophenolic acid area under the concentration-time curve in hematopoietic cell transplantation recipients. JClin Pharmacol 2011, 52:1654-1664.
33. Bleyzac N., Souillet G., Magron P., et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001, 28:743-751.
34. McCune J.S., Batchelder A., Guthrie K.A., et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009, 85:615-622.
35. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. Arandomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999, 68:261-266.
36. Le Meur Y., Buchler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7:2496-2503.
37. Glander P., Hambach P., Braun K.P., et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004, 4:2045-2051.
38. Laverdiere I., Caron P., Couture F., et al. Liquid chromatography-coupled tandem mass spectrometry based assay to evaluate inosine-5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients. Anal Chem 2012, 84:216-223.